Patients Central nervous system Tremor Ataxia Dizziness Blurred speech Visual disturbances Thought disorder Fatigue Paresthesias Nightmares Insomnia Confusion Headaches Tinnitus Hallucinations Gastrointestinal Nausea and vomiting Hepatitis Cardiovascular Aggravation of arrhythmia Increase in CHF Oth

@inproceedings{Hohnloser2005PatientsCN,
  title={Patients Central nervous system Tremor Ataxia Dizziness Blurred speech Visual disturbances Thought disorder Fatigue Paresthesias Nightmares Insomnia Confusion Headaches Tinnitus Hallucinations Gastrointestinal Nausea and vomiting Hepatitis Cardiovascular Aggravation of arrhythmia Increase in CHF Oth},
  author={Stefan H. Hohnloser and Helmut W. Lange and E. A. Raeder and Philip J. Podrid and Bernard Lown},
  year={2005}
}
Tocainide was administered to 228 patients referred for treatment of recurrent ventricular tachyarrhythmias that were refractory to therapy with conventional antiarrhythmic drugs. After baseline studies, 1200 to 2400 mg tocainide/day was given for 4 days. Tocainide was effective in 49% of 180 patients evaluated with monitoring and exercise testing and in 35% of 48 patients undergoing electrophysiologic testing. No clinical parameter predicted the response to tocainide, although there was a… CONTINUE READING
0 Citations
30 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Lown B: Propafenone: A new agent for ventricular arrhythmias

  • PJ Podrid
  • J Am Coll Cardiol
  • 1984

Similar Papers

Loading similar papers…